Publications

Mark Nuijten, Marja Pronk, John Hutton, Peter van Hasselt, Cor Oosterwijk and Frans Rutten.
Clinical and economic issues complicating cost-effectiveness analysis of orphan diseases.
The Eurobiotech Journal 2017;1(2):132-7.

 

Mark JC Nuijten, Josbert J Keller, Caroline E Visser, Ken Redekop, Eric Claassen, Peter Speelman, Marja H Pronk.
Cost-effectiveness in Clostridium difficile treatment decision-making.
World J Clin Cases 2015 November 16; 3(11): 935-941.

 

Koos Brouwers, Jeroen Hendriks, Hans van Laarhoven, Gerlof Jukema, Marja Pronk.
Patient perspective in the reimbursement assessment of direct anticoagulant products for atrial fibrillation and venous thromboembolism.
Pharm Weekbl 2015:9(4):72-7.

 

Mark Nuijten, Marja Pronk.
Financial Valuation Algorithm for the Assessmentof the Future Sales of a New, Innovative Medicinal Product.
The Journal of Private Equity. Summer 2014, Vol. 17, No. 3: pp. 35-44. DOI: 10.3905/jpe

 

Marja Pronk, Astrid Rijken-Knol and Gouke Bonsel.
Report of review study on Consistency in Dutch Reimbursement Assessment 
by the Health Care Insurance Board (CVZ): In-hospital medicinal products.
The Netherlands, 9 January 2009

 

Marja Pronk, Martine van der Zeijst and Gouke Bonsel.
Report of review study on Consistency in Dutch Reimbursement Assessment 
by the Health Care Insurance Board (CVZ): Out-patient medicinal products..
The Netherlands, 16 June 2008

 

Marja Pronk, Bart van der Lelie, Carla Schoonderbeek.
Expensive medicinal Products needs to be financed differently: the function of the Dutch Policy rule is still not optimal. 
Medisch Contact 2007;43: 1768-70.

 

Marja Pronk, Carla Schoonderbeek.
Medicinal Products with added value: Innovation of the Dutch price reference system is urgently needed. 
Medisch Contact 2007;15: 632-5.

 

Marja H. Pronk, Carla J.R.A. Schoonderbeek, Gouke J. Bonsel. 
The reimbursement structure of in- and out-patient market access: two different systems on one pillow. 
TSG 2005; 3: 145-151.

 

Marja H. Pronk, Gouke J. Bonsel. 
Out-patient drug policy by clinical assessment rather than financial constraints? The gate-keeping function of the out-patient drug-reimbursement system in the Netherlands. 
Eur J Health Econom 2004; 5:2740-277.

 

M.H. Pronk, G.J. Bonsel, A. van der Kuy.
The budget control function of the Dutch Price Reference System.
Ned Tijdschrift Geneesk 2002; 37:1729-33.

 

Smet PAGM de, Bonsel G, Kuy van der, Hekster YA, Pronk MH, Brorens MJA, Lockefeer JHM, Nuijten MJC.
Introduction to the Pharmacoeconomics of Herbal Medicines. 
Pharmacoeconomics 2000; 18 (11):1-7.

 

Nuijten MJC, Pronk MH, Brorens MJA, Hekster YA, Lockefeer JHM
Reporting Format for Ecnomic Evaluation Part II : Focus on modelling studies.
Pharmacoeconomics 1998; 14 (3):259-68.

 

Nuijten MJC, Brorens MJA, Hekster YA, Kuy van der, Lockefeer JHM, Smet PAGM de, Bonsel GJ and Pronk MH.
Reporting format on Economic Evaluation Part I : Application to the Dutch Healthcare System.
Pharmacoeconomics 1998;14(2):159-63.

 

Pronk MH, Bonsel GJ, Brorens MJA, Hekster YA, Kuy A. van der, Smet PAGM de.
Evaluation of the therapeutic value of drugs: efficacy, applicability, effectiveness and efficiency. 
Ned Tijdsch Geneesk 1998 (142);697-701.

 

Pronk MH, Brorens MJA, Eschuazier AM, Hardens M, Hekster YA, Kuy A. van der, Lockefeer JHM, Smet PAGM de.
Proposal for standardised reporting of economic evaluations.
Pharm Weekbl 1997; 132(9):268-71.